scPharmaceuticals Inc. (NASDAQ:SCPH) Given Consensus Recommendation of “Buy” by Analysts

scPharmaceuticals Inc. (NASDAQ:SCPHGet Rating) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is $17.83.

Several equities research analysts recently issued reports on the company. SVB Leerink lifted their price objective on scPharmaceuticals from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, November 10th. Cowen started coverage on shares of scPharmaceuticals in a research note on Thursday, December 1st. They issued an “outperform” rating and a $25.00 target price on the stock. Maxim Group raised their target price on shares of scPharmaceuticals from $10.00 to $13.00 in a research note on Tuesday, October 11th. Cowen started coverage on shares of scPharmaceuticals in a research note on Thursday, December 1st. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of scPharmaceuticals in a research note on Friday, October 21st. They issued a “buy” rating and a $14.00 target price on the stock.

scPharmaceuticals Trading Down 1.3 %

SCPH stock opened at $6.14 on Friday. scPharmaceuticals has a 12-month low of $3.68 and a 12-month high of $7.96. The stock has a market cap of $168.44 million, a price-to-earnings ratio of -4.83 and a beta of 0.25. The business’s 50-day moving average is $6.62 and its 200 day moving average is $5.81.

scPharmaceuticals (NASDAQ:SCPHGet Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.04. As a group, equities analysts forecast that scPharmaceuticals will post -1.42 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Orbimed Advisors Llc purchased 762,380 shares of scPharmaceuticals stock in a transaction dated Friday, November 25th. The shares were purchased at an average price of $5.25 per share, with a total value of $4,002,495.00. Following the transaction, the insider now owns 5,328,328 shares in the company, valued at $27,973,722. The purchase was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Trading of scPharmaceuticals

Several institutional investors have recently made changes to their positions in SCPH. Virtu Financial LLC purchased a new stake in shares of scPharmaceuticals during the 2nd quarter valued at approximately $53,000. Commonwealth Equity Services LLC purchased a new stake in scPharmaceuticals in the second quarter valued at approximately $74,000. Cubist Systematic Strategies LLC purchased a new stake in scPharmaceuticals in the third quarter valued at approximately $75,000. State Street Corp raised its position in scPharmaceuticals by 15.0% in the second quarter. State Street Corp now owns 17,360 shares of the company’s stock valued at $84,000 after purchasing an additional 2,260 shares during the period. Finally, Envestnet Asset Management Inc. purchased a new stake in scPharmaceuticals in the third quarter valued at approximately $92,000. Hedge funds and other institutional investors own 53.90% of the company’s stock.

About scPharmaceuticals

(Get Rating)

scPharmaceuticals, Inc engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting.

Read More

Analyst Recommendations for scPharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.